Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669833 · ClinicalTrials.gov registry record · Phase 3
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
A Phase 3 study of Psoriatic Arthritis, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
- 14
- Study locations
NCT05669833: Recruiting Phase 3 study of Psoriatic Arthritis, sponsored by University of Pennsylvania.
NCT05669833 is a Phase 3 study of Psoriatic Arthritis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 63 participants, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (93% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05669833, a Phase 3 study of Psoriatic Arthritis, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
- 14
- Study locations
Study Summary
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Primary Outcome
Clinical Disease Activity in Psoriatic Arthritis (cDAPSA): a combination score of tender joint count, swollen joint count, patient assessment of pain, and patient global assessment of disease activity. Scale from 0-154 where higher figures indicate worse status. Remission is considered ≤4 and low disease activity \>4 to ≤13.
Conditions Studied
Interventions
- DRUG Guselkumab
- DRUG Golimumab
Study Locations (14)
Florida
- Family Arthritis Center - Loxahatchee Groves
- Healing Rheumatology - Plant City
- Southwest Florida Rheumatology - Riverview
Ohio
- Cincy Arthritis - Blue Ash
- Southern Ohio Rheumatology - Wheelersburg
Texas
- Heritage Rheumatology and Arthritis Care - Colleyville
- Texas Arthritis Center - El Paso
Georgia
- Parris and Associates - Lilburn
Massachusetts
- University of Massachusetts Chan Medical School - Worcester
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- New York University - New York
Pennsylvania
- Hospital at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-07-14 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
What NCT05669833 shows while recruiting
NCT05669833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Guselkumab is the first listed.
NCT05669833 lists 14 locations in 10 states (Florida, Ohio, Texas).
Frequently Asked Questions
What is clinical trial NCT05669833 about?
NCT05669833 is a clinical study titled "Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients". The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
What is the current status of trial NCT05669833?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2023-07-14. Estimated completion is 2026-10.
What conditions does trial NCT05669833 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT05669833?
The interventions under investigation include: Guselkumab (DRUG), Golimumab (DRUG).
Who is sponsoring clinical trial NCT05669833?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05669833 being conducted?
This trial has 14 study locations across Florida, Georgia, Massachusetts, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05669833's enrollment target sits among peer trials
63 42nd of 48 higher than 7 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI